Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposal

Journal of Medicinal Chemistry

Volumn 49, Issue 25, 2006, Pages 7545-7548

  Clairmont, Kevin B ^a   Buckholz, Thomas M ^a   Pellegrino, Carla M ^a   Buxton, Joanne M ^a   Barucci, Nicole ^a   Bell, Andrea ^a   Ha, Sha ^a   Li, Fugang ^a   Claus, Thomas H ^a   Salhanick, Arthur I ^a   Lumb, Kevin J ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCOSE; INSULIN; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2 AGONIST;

ACETYLATION; AMINO TERMINAL SEQUENCE; ARTICLE; DIABETES MELLITUS; DRUG CLEARANCE; ENZYME STABILITY; GLUCOSE TRANSPORT; HALF LIFE TIME; IN VIVO STUDY; INSULIN RELEASE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN ENGINEERING; PROTEIN SECRETION;

ACETYLATION; ANIMALS; ANTIGENS, CD26; CHO CELLS; CRICETINAE; CRICETULUS; GLUCOSE; HALF-LIFE; HUMANS; HYDROLYSIS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PEPTIDES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II;

EID: 33845477003     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0609059     Document Type: Article

References (19)

1. Arulmozhi, D. K.; Portha, B. GLP-1 based therapy for type 2 diabetes. Eur. J. Pharm. Sci. 2006, 28, 96-108.
2. Deacon, C. F.; Holst, J. J. Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes. Int. J. Biochem. Cell Biol. 2006, 38, 831-844.
3. Riddle, M. C.; Drucker, D. J. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006, 29, 435-449.
4. Tsutsumi, M.; Claus, T. H.; Liang, Y.; Li, Y.; Yang, L.; Zhu, J.; Dela Cruz, F.; Peng, X.; Chen, H.; Yung, S. L.; Hamren, S.; Livingston, J. N.; Pan, C. Q. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: A potential therapy for type 2 diabetes. Diabetes 2002, 51, 1453-1460.
5. Vaudry, D.; Gonzalez, B. J.; Basille, M.; Yon, L.; Fournier, A.; Vaudry, H. Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacol. Rev. 2000, 52, 269-324.
6. Harris, J. M.; Chess, R. B. Effect of PEGylation on pharmaceuticals. Nat. Rev. Drug Discovery 2003, 2, 214-221.
7. Pan, C. Q.; Li, F.; Tom, I.; Wang, W.; Dumas, M.; Froland, W.; Yung, S. L.; Li, Y.; Roczniak, S.; Claus, T. H.; Wang, Y. J.; Whelan, J. P. Engineering novel VPAC2 selective agonists with improved stability and glucose lowering activity in vivo. J. Pharmacol. Exp. Ther., accepted for publication.
8. 7
9. Lambeir, A. M.; Durinx, C.; Proost, P.; Van Damme, J.; Scharpe, S.; De Meester, I. Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett. 2001, 507, 327-330.
10. Yung, S. L.; Dela Cruz, F.; Hamren, S.; Zhu, J.; Tsutsumi, M.; Bloom, J. W.; Caudle, M.; Roczniak, S.; Todd, T.; Lemoine, L.; MacDougall, M.; Shanafelt, A. B.; Pan, C. Q. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J. Biol. Chem. 2003, 278, 10273-10281.
11. Engel, M.; Hoffmann, T.; Wagner, L.; Wermann, M.; Heiser, U.; Kiefersauer, R.; Huber, R.; Bode, W.; Demuth, H. U.; Brandstetter, H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5063-5068.
12. Rasmussen, H. B.; Branner, S.; Wiberg, F. C.; Wagtmann, N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol. 2003, 10, 19-25.
13. Salhanick, A. I.; Clairmont, K. B.; Buckholz, T. M.; Pellegrino, C. M.; Ha, S.; Lumb, K. J. Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide. Bioorg. Med. Chem. Lett. 2005, 15, 4114-4117.
14. Bailon, P.; Berthold, W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1998, 1, 352.
15. Goodson, R. J.; Katre, N. V. Site-directed PEGylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 1990, 8, 343-346.
16. Bailon, P.; Palleroni, A.; Schaffer, C. A.; Spence, C. L.; Fung, W. J.; Porter, J. E.; Ehrlich, G. K.; Pan, W.; Xu, Z. X.; Modi, M. W.; Farid, A.; Berthold, W.; Graves, M. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjugate Chem. 2001, 12, 195-202.
17. Rosendahl, M. S.; Doherty, D. H.; Smith, D. J.; Carlson, S. J.; Chlipala, E. A.; Cox, G. N. A long-acting, highly potent interferon α-2 conjugate created using site-specific PEGylation. Bioconjugate Chem. 2005, 16, 200-207.
18. Hughes, T. E.; Mone, M. D.; Russell, M. E.; Weldon, S. C.; Villhauer, E. B. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]-acetyl]-2-cyano- (S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 1999, 38, 11597-11603.
19. Pan, C. Q.; Buxton, J. M.; Yung, S. L.; Tom, I.; Yang, L.; Chen, H.; MacDougall, M.; Bell, A.; Claus, T. H.; Clairmont, K. B.; Whelan, J. P. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J. Biol. Chem. 2006, 281, 12506-12515.